unknown
Stage
About
Axovia Therapeutics is developing gene therapies using AAV9 vectors to treat genetic ciliopathies, including Bardet-Biedl Syndrome, aiming to prevent blindness and reverse obesity caused by mutations in the BBS1 gene.
Explore Axovia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.